Blue Jet Healthcare Limited · NSE:BLUEJET
Blue Jet Healthcare — Q2 & H1 FY27 Earnings Presentation
44 slides from Blue Jet Healthcare's earnings presentation, Nov 5, 2026
Slide 1: Exchange filing cover letter for results presentation
November 5, 2026 To, BSE Limited National Stock Exchange of India Limited Phiroze Jeejebhoy Towers “Exchange Plaza” Dalal Street Bandra-Kurla Complex, Bandra (East) Mumbai - 400 001 Mumbai - 400051 Scrip Code (BSE): 544009 Symbol: BLUEJET Sub: Analysts/Investors Presentation on Financial Results for
Slide 2: Investor Presentation Q2 & H1 FY27
Investor Presentation Q2 & H1 FY27 1
Slide 3: Disclaimer
Disclaimer The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any i
Slide 4: Table of Content
Table of Content 1 Q2 & H1 FY27 Financials 2 Company at a Glance 3 Contrast Media Intermediates 4 High Intensity Sweeteners 5 Pharma Intermediates & API 6 R&D Capabilities 7 Growth Strategy 8 Management and Board of Directors 3
Slide 5: Q2 & H1 FY27 Financials
‘| Q2 & H1 FY27 Financials ~ @ in 4 Gs aS Aw, Lys l » gf os Z 2 v ‘ uff
Slide 6: Q2 & H1 FY27 Earnings Highlights
Q2 & H1 FY27 Earnings Highlights Business Updates Half Yearly Revenue Quarterly Revenue Growth Growth ✓ This quarter we clocked Highest Quarterly Sales at Rs 3,757mn. ✓ The R&D centre at Hyderabad facilities are operational now with 40 resources +28% +29% onboarded & activity started. QoQ YoY ✓ The
Slide 7: Q2 FY27 vs Q1 FY27 (QoQ) Earnings Highlights
Q2 FY27 vs Q1 FY27 (QoQ) Earnings Highlights Financial Highlights ✓ Revenue from Operations in Q2 September 26 was Rs 3,757mn – Highest Quarterly Sales reported, EBITDA Rs 1,188mn (32% Margin) and PAT Rs 1,025mn (27% Margin) ✓ Revenue from Operations in Q1 June 26 was Rs 2,931mn, EBITDA Rs 981mn (33
Slide 8: Q2 FY27 vs Q2 FY26 (YoY) Earnings Highlights
Q2 FY27 vs Q2 FY26 (YoY) Earnings Highlights Financial Highlights ✓ Revenue from Operations in Q2 September 26 was Rs 3,757mn mn, EBITDA Rs 1,188mn (32% Margin) and PAT Rs 1,025mn (27% Margin) ✓ Revenue from Operation in Q2 September 25 was Rs 1,655mn, EBITDA Rs 549mn (33% Margin) and PAT Rs 521mn (
Slide 9: H1 FY27 vs H1 FY26 Earnings Highlights
H1 FY27 vs H1 FY26 Earnings Highlights Financial Highlights ✓ Revenue from Operation: H1 FY27 Revenue from Operation was Rs 6,689mn, EBITDA Rs 2,168mn (32% Margin) and PAT Rs 1,808mn (27% Margin). ✓ Revenue from Operation : H1 FY26 Revenue from Operations was Rs 5,202mn, EBITDA Rs 1,759mn (34% Margi
Slide 10: Q2 FY27 vs Q1 FY27 Financial Performance – Key Metrics
Q2 FY27 Vs Q1 FY27 Financial Performance – Key Metrics Revenue from Operations** – Growth Trends (₹ Mn) QoQ -30.3% 25.1% 51.6% 17.6% 28.1% Growth: Q1 FY27 Q2 FY27 3,738 2,917 1,833 1,450 1,210 1,159 397 277 152 178 High-intensity sweetners Contrast media intermediates Pharma intermediates and API Ot
Slide 11: Q2 FY27 vs Q2 FY26 Financial Performance – Key Metrics
Q2 FY27 Vs Q2 FY26 Financial Performance – Key Metrics Revenue from Operations** – Growth Trends (₹ Mn) YoY -18.6% 79.6% 322.1% 184.3% 127.4% Growth: Q2 FY26 Q2 FY27 3,738 1,833 1,644 1,450 807 340 277 434 63 178 High-intensity sweetners Contrast media intermediates Pharma intermediates and API Othe
Slide 12: H1 FY27 vs H1 FY26 Financial Performance – Key Metrics
H1 FY27 Vs H1 FY26 Financial Performance – Key Metrics Revenue from Operations** – Growth Trends (₹ Mn) YoY -2.2% 46.6% 19.1% 107.2% 28.4% Growth: H1 FY26 H1 FY27 6,655 5,181 2,609 2,554 3,043 1,779 689 674 330 159 High-intensity sweetners Contrast media intermediates Pharma intermediates and API Ot
Slide 13: Profit and Loss Statement
Profit and Loss Statement Particulars (Rs. Mn) Q2 FY27 Q1 FY27 QoQ Q2 FY26 YoY H1 FY27 H1 FY26 YoY Revenue from Operations 3,757 2,931 28.2% 1,655 127.1% 6,689 5,202 28.6% Cost Of Goods Sold 1,933 1,371 579 3,304 2,408 Gross Profit 1,824 1,560 16.9% 1,076 69.5% 3,384 2,795 21.1% Gross Margin 48.5% 5
Slide 14: Financial Performance over the years – Key Metrics
Financial Performance over the years – Key Metrics Revenue from Operations** – Growth Trends (₹ Mn) CAGR: -4.4% 0.9% 64.0% 178.0% 8.6% 10,247 9,424 6,768 7,185 7,084 6,655 4,778 5,070 4,799 4,951 4,622 4,039 2,609 2,978 3,043 1,575 1,759 1,282 1,335 1,314 674 947 412 340 3 16 55 251 180 330 High-int
Slide 15: Financials for the last six years
Financials for the last six years Summary Statement of Profit and Loss Summary Statement of Assets and Liabilities H1 Particulars (₹ Mn) FY22 FY23 FY24 FY25 FY26 H1 FY27 Particulars (₹ Mn) FY22 FY23 FY24 FY25 FY26 FY27 I. Assets Revenue from Operations 6,835 7,210 7,116 10,300 9,473 6,689 Property,
Slide 16: Shareholder Information
Shareholder Information Shareholding as on 30th September 2026 Share Information as on 30th September 2026 NSE Ticker BLUEJET Others BSE Ticker 544009 18.5% Market Cap (₹ Cr) (BSE) 10,198 FII % free-float 26.9% 0.8% DII Free-float market cap (₹ Cr) 2,739 7.5% Cash & Cash Equivalents + Treasury Inves
Slide 17: Company at a Glance
. » gf Z 4 Company ata > ata Glance v SS 2
Slide 18: Our Journey
Our Journey • Established Jet Chemicals • Began manufacturing high- • Entered the X-ray contrast Private Limited with Shahad intensity sweeteners - media sector, with a basic facility (Unit I) saccharin and its salts building block (5- NIPA) 1968 1970 2000 • Commenced manufacturing of • Commenced se
Slide 19: Who we are
Who we are A specialty pharmaceutical and healthcare ingredient and intermediate company, offering niche products with an approach of “Collaboration, Development, Manufacturing” to CDMO business. 18
Slide 20: Blue Jet Healthcare at a glance
Blue Jet Healthcare at a glance 511 1,175.60 KL ₹ 9,473.2 mn ₹ 2,940.99 mn Commercialized product reaction capacity across Revenue (FY26) (13.7% EBITDA (FY26) (31.0% portfolio (FY26) 3 facilities (FY26) FY21-26 CAGR) margin) Key metrics 3.75x ₹ 3,619 mn 24.9% 19.9% Cash and Cash Equivalents + Fixed
Slide 21: Overview of our Product Categories
Overview of our Product Categories Contrast Media High Intensity Pharma Intermediates Intermediates Sweeteners & APIs ◼ Contrast media are agents used in medical ◼ High-intensity sweetener business involves ◼ Collaboration with innovator pharmaceutical imaging to enhance the visibility of body tissu
Slide 22: Contrast Media Intermediates
3 Contrast Media Intermediates 21
Slide 23: Overview of Contrast Media and its growth drivers
Overview of Contrast Media and its growth drivers What is contrast media? Types of contrast media ◼ Chemical agents that enhances the contrast of an imaging ◼ X-ray / Computed Tomography (CT) contrast agents: Iodine- modality in diagnostic imaging, thereby aiding diagnosis of based contrast media ag
Slide 24: The global Contrast Media industry is highly concentrated
The global Contrast Media industry is highly concentrated Global Contrast Media Formulation Market Global Medical Imaging Market (USD Bn) Revenue Share of Contrast Agent type, 2024 Revenue (USD Bn) CAGR, 2024-2029F - 6.4% CAGR, 2019-2024: 6.8% 9.5 2% 72.0 8.8 67.7 CAGR, 2024-2029F: 7.2% 8.2 63.6 7.7
Slide 25: High entry barriers for key intermediates' vendors
High entry barriers for key intermediates’ vendors Characteristics of the Contrast Media Intermediate Blue Jet's positioning Contrast Media market product category performance ✓ More than two decades of experience CAGR: 0.9 % ✓ 75%+ of exports of a selected contrast media Strict internal standards i
Slide 26: Key benefits
Continue to forward integrate into more advanced intermediates for Contrast Media Strong product development and process optimization capabilities underpinned by in-house R&D capabilities Capture larger wallet share with existing customers Focus on molecules with customer interest and strategy in ei
Slide 27: High Intensity Sweeteners
4 High Intensity Sweeteners 26
Slide 28: Blue Jet's positioning in High Intensity Sweetener
Blue Jet’s positioning in High Intensity Sweetener Blue Jet's positioning High Intensity Sweeteners product category performance Products ◼ Adherence to strict internal standards to ensure consistency in quality, performance, CAGR: -4.4% taste, and impurity profile Revenue (₹ mn) ◼ Multiple products
Slide 29: Global High Intensity Sweeteners Market
Global High Intensity Sweeteners Market Global Artificial Sweeetener Market Revenue (USD Mn) Global High-intensity Sweetneer Market, Revenue share by segments, 2024 4,495 3% 3% 4,213 3,948 3,700 Sucralose 3,468 5% 3,250 Aspartame 3,060 9% 2,713 2,882 2,406 2,555 40% Saccharin Stevia 12% Acesulfame K
Slide 30: Pharma Intermediates & API
5Pharma Intermediates & API 29
Slide 31: Trends and features of the Pharma Intermediates and APIs Product Category
Trends and features of the Pharma Intermediates and APIs Product Category Key trends in Pharma Intermediates and CDMO market Revenue and capacity utilization predictability Increased propensity to outsource manufacturing of intermediates & APIs for the CDMO ◼ Enables asset light model and ability to
Slide 32: Overview of Blue Jet's Pharma Intermediates and APIs Product Category
Overview of Blue Jet’s Pharma Intermediates and APIs Product Category Pharma Intermediate and APIs ◼ Commenced manufacturing pharma intermediates two decades ago, leveraging the customer relationships through high-intensity product category performance sweetener business ◼ Key focus areas include hi
Slide 33: CDMO Potential in API for Indian Players
CDMO Potential in API for Indian Players Global API CDMO Market by Global CDMO Market by Modality (USD Bn) Global CDMO Market Revenue (USD Bn) Innovation Type (USD Bn) 190.0 CAGR, 2019-2024 - 6.9% 190 CAGR, 2024-2029F - 8.1% 176 135.0 55.0 162 128.8 150 139 93.1 129 68.8 92.1 120 35.7 106 113 67.8 9
Slide 34: Leverage long-standing customer relationships to enter pharma intermediate adjacencies
Leverage our long-standing customer relationships to continue entering adjacencies in the pharma intermediate and API category Focus on three niche areas in providing CDMO services Blue Jet’s positioning Investigational new drugs and new chemical Leverage long-standing relationships with innovator e
Slide 35: R&D Capabilities
6 R&D Capabilities 34
Slide 36: Our R&D framework
Our R&D framework R&D capabilities across Process research Portfolio Process Process scale-up Regulatory filings evaluation development and validation and approvals Analytical research Chemistry research Method Characterization of Polymorphism Pharmaceutical salt High pressure Literature search deve
Slide 37: Strengthening R&D Capabilities with Our New Hyderabad Facility
Strengthening R&D Capabilities with Our New Hyderabad Facility 36
Slide 38: Sustainability
Sustainability Various initiatives on energy efficiency, renewable energy, and water conservation to reduce carbon footprint Invested in windmills with installed capacity of 3.3MW Created carbon sinks Focus on enhancing through tree plantations energy efficiency Effluent treatment plants with Minimi
Slide 39: Growth Strategy
ly. 7 Fe Growth Strategy
Slide 40: Our strategies
Our strategies Focus on operational efficiency and mitigation of supply chain risks Continue to forward integrate into Continue to invest in R&D more advanced intermediates for infrastructure and capabilities Contrast Media Leverage our long-standing Build additional production capacity customer rel
Slide 41: Management and Board of Directors
8 Management and Board of Directors 40
Slide 42: Experienced and visionary management team backed by independent Board of Directors
Experienced and visionary management team backed by independent - Board of Directors Management team Akshay Bansarilal Shiven Akshay Naresh Suryakant Shah Ganesh Vimalendu Kumar Singh Chandrashekar Parenky Arora Arora Executive Director, Head Karuppannan (V.K. Singh) President – Research and Executi
Slide 43: Management team and independent board of directors (cont'd)
Experienced and visionary management team backed by independent Board of Directors (cont’d) Management team (cont’d) Independent board of directors Popat B Kedar Sweta Poddar Girish Paman Preeti Gautam Divya Sameer Priyanka Yadav Executive Director Company Secretary and Vanvari Mehta Momaya Independ
Slide 44: Thank you!
Thank you! BLUE JET HEALTHCARE LIMITED INVESTOR RELATIONS AT Registered Office Blue Jet Healthcare Limited 701,702, 7th Floor, Bhumiraj Costarica, Sanjay Sinha, Deputy Chief Financial Officer Sector 18, Sanpada, Navi Mumbai Thane [email protected] 400705, Maharashtra, India NSE: BLU
Blue Jet Healthcare — Q2 & H1 FY27 Earnings Presentation on 6ix